Ofloxacin shown to be effective in a second-line regimen for the treatment of H. pylori infection

This is the latest of a number of studies showing that ofloxacin is an effective component of second-line therapy for the treatment of Helicobacter pylori infection. The present study was carried out by staff in the Department of Gastroenterology and Hepatology, Isfahan University of medical Sciences, Isfahan, Iran.
The study compared the safety and efficacy of a new quadruple regimen (azithromycin, ofloxacin, bismuth and omeprazole) with a standard second line treatment (amoxicillin, clarithromycin, bismuth and omeprazole) given for 2 weeks. A total of 220 H. pylori-positive patients were recruited who failed to respond to treatment with metronidazole, amoxicillin, omeprazole and bismuth. The rate of H. pylori eradication was higher in the ofloxacin group on both an intention-to-treat and per protocol basis (77.3% versus 64.5% and 86.7% versus 74.7%, respectively). The authors conclude that a two-week treatment with the ofloxacin-containing regimen was a safe and effective second-line therapy.

Helicobacter. 2010 Apr;15(2):154-9.

Source : http://www.ncbi.nlm.nih.gov/pubmed/20402818?dopt=Abstract